<table>
<thead>
<tr>
<th>Indication</th>
<th>Target/marker/pathway</th>
<th>Summary</th>
<th>Licensing status</th>
<th>Publication and contact information</th>
</tr>
</thead>
</table>
| Cardiovascular disease     | Atherosclerosis                                                                        | Nonhuman primate studies suggest combining MYLIP inhibitors with LXR agonists could help treat atherosclerosis. LXR agonists used in atherosclerosis treatment raise plasma low-density lipoprotein (LDL) levels as a side effect. In normal nonhuman primates, an LXR agonist increased plasma LDL levels and hepatic Mylir mRNA levels compared with vehicle. In nonhuman primates fed a high-fat diet, an antisense oligonucleotide against MYLIP attenuated LXR agonist–induced increases in plasma LDL levels. Ongoing work includes screening for small molecule MYLIP inhibitors. Exelixis Inc. and Bristol-Myers Squibb Co. have XL041 (BMS-852927), a small molecule modulator of LXR, in Phase I testing to treat metabolic syndrome. Vitae Pharmaceuticals Inc. has two LXR-β (NR1H2) agonists in preclinical development: VTP-38443 for acute coronary syndrome and VTP-38543 for dermatitis. | Patented; available for licensing | Hong, C. et al. Cell Metab.; published online Nov. 4, 2014; doi:10.1016/j.cmet.2014.10.001  
Contact: Peter Tontonoz, University of California, Los Angeles, Calif.  
e-mail: ptontonoz@mednet.ucla.edu  
Contact: Ryan E. Temel, University of Kentucky, Lexington, Ky.  
e-mail: ryan.temel@uky.edu |